|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Contract assets | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Current assets held for sale | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangibles, net | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, temporary equity and stockholders’ deficit | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Current portion of debt obligations | ||||||||||||||||||||
| Contract liabilities | ||||||||||||||||||||
| Current liabilities held for sale | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Debt obligations | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Temporary equity | ||||||||||||||||||||
| Preferred Stock Series A-3 and Preferred Stock Series A-4, $0.001 par value Shares authorized: 20,000,000; Shares issued and outstanding: 6,125 of Series A-3; 1,937 of Series A-4 | ||||||||||||||||||||
| Series A-3 and A-4 Preferred Stock | ||||||||||||||||||||
| Series A-3 , A-4 And C Preferred Stock | ||||||||||||||||||||
| Series A-3 , A-4 Preferred Stock | ||||||||||||||||||||
| Redeemable non-controlling interests | ||||||||||||||||||||
| Total temporary equity | ||||||||||||||||||||
| Stockholders’ deficit | ||||||||||||||||||||
| Common stock, $0.001 par value Shares authorized: 250,000,000; Shares issued: 13,818,904; Shares outstanding: 13,641,866 and 13,655,062, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock, at cost: 177,038 and 163,842 shares, respectively | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total INNOVATE Corp. stockholders’ deficit | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities, temporary equity and stockholders’ deficit | ||||||||||||||||||||
Loading...
